Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 20;19(3):242-248.
doi: 10.17305/bjbms.2019.3970.

Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients

Ilija Vladimir Baroš  1 , Nataša Tanasković, Ulrika Pellas, Živka Eri, Ljiljana Tadić Latinović, Tibor Tot
Affiliations

Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients

Ilija Vladimir Baroš et al. Bosn J Basic Med Sci. .

Abstract

Determination of human epidermal growth factor receptor 2 (HER2) status is important for adequate treatment of breast cancer (BC) patients. The novel HER2 gene protein assay (GPA) is particularly convenient, as it allows the simultaneous assessment of HER2 protein expression and gene amplification at individual cell level. Here we investigated the frequency of internodal HER2 heterogeneity in axillary lymph node macrometastases of BC patients and compared HER2 status between primary breast tumor and its metastases. We included a total of 41 female patients operated between 2014 and 2015 for primary BC with axillary lymph node macrometastases. Representative paraffin blocks of metastatic lymph nodes were sectioned and the slides were stained using the GPA in 38 BC cases. GPA results were assessed according to the ASCO/CAP 2013 criteria. We analyzed 12586 individual tumor cells, 120 cells per section of each metastatic lymph node. HER2 status differed between the primary tumor and its metastases in 5/38 cases (13.2%). In patients with at least two metastatic nodes, the HER2 status of lymph node metastases was only slightly different in 4/23 cases (17.4%). Our results indicate rare but substantial differences in HER2 status between primary breast tumor and its axillary lymph node metastases that may direct the choice and outcomes of targeted therapy in BC patients. The impact of the rare and subtle internodal HER2 heterogeneity evidenced in this study remains uncertain. Determining the HER2 status of lymph node metastases in BC seems to be rational, but assessing a limited number of metastatic nodes may be sufficient.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Representative breast cancer cases with HER2-negative (A), HER2-equivocal (B), and HER2-positive (C) lymph node metastases, stained using HER2 gene protein assay. HER2: Human epidermal growth factor receptor 2.
FIGURE 2
FIGURE 2
Breast cancer lymph node metastasis showing intratumoral heterogeneity (HER2 gene protein assay). A) low magnification image; B) high magnification image of the area marked with the rectangle in A. HER2: Human epidermal growth factor receptor 2.
See this image and copyright information in PMC

References

    1. World Cancer Research Fund [Internet] Diet, nutrition, physical activity and breast cancer. London: WCRF International; [[cited 2018 May 23]]. Available from: https://www.wcrf.org/dietandcancer/about .
    1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. https://doi.org/10.1056/NEJM200103153441101. - PubMed
    1. Killelea BK, Chagpar AB, Horowitz NR, Lannin DR. Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer:43,485 cases from the National Cancer Database treated in 2010 and 2011. Am J Surg. 2017;213(2):426–32. https://doi.org/10.1016/j.amjsurg.2016.05.018. - PubMed
    1. Nitta H, Kelly BD, Padilla M, Wick N, Brunhoeber P, Bai I, et al. A gene-protein assay for human epidermal growth factor receptor 2 (HER2):Brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol. 2012;7(1):60. https://doi.org/10.1186/1746-1596-7-60. - PMC - PubMed
    1. Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, et al. HER2 in situ hybridization in breast cancer:Clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014;27(1):4–18. https://doi.org/10.1038/modpathol.2013.103. - PubMed